PT  - JOURNAL ARTICLE
AU  - Abram Bunya Kamiza
AU  - Segun Fatumo
AU  - Mwiza Gideon Singini
AU  - Chih-Ching Yeh
AU  - Tinashe Chikowore
TI  - Chronic hepatitis B infection is causally associated with extrahepatic cancers: a Mendelian randomization study
AID  - 10.1101/2021.03.13.21253528
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.13.21253528
4099  - http://medrxiv.org/content/early/2021/03/15/2021.03.13.21253528.short
4100  - http://medrxiv.org/content/early/2021/03/15/2021.03.13.21253528.full
AB  - Overwhelming evidence suggests that chronic hepatitis infection is associated with extrahepatic cancers. However, uncertainty persists about the causal role of chronic hepatitis infection on extrahepatic cancers, as much of the current evidence originates from observational studies which are prone to confounding. Herein we performed two-sample Mendelian randomization (MR) to examine the causal associations between chronic hepatitis infection and extrahepatic cancers. Genetic variants associated with chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection were identified from a genome-wide association study and used as instrumental variables in our analysis. Summary level data for cancer of the biliary tract, cervix, colorectum, endometrium, esophagus, gastric, liver, lung, ovary and pancreas were obtained from the Biobank Japan. Using the inverse variance weighted methods, we found chronic HBV infection to be causally associated with gastric cancer (odds ratio [OR] = 1.19 and 95% confidence interval [CI] = 1.13-1.25, P-value = 0.001) and lung cancer (OR = 1.21, 95% CI = 1.14-1.28, P-value = 0.001). Moreover, chronic HBV infection (OR = 1.34, 95% CI = 1.17-1.53, P-value = 0.007) and chronic HCV infection (OR = 2.75, 95% CI = 2.21-3.42, P-value = 0.0008) were all causally associated with liver cancer, supporting a well-established association between chronic hepatitis infection and liver cancer. In conclusions, our MR findings revealed that chronic HBV infection is causally associated with extrahepatic cancers including gastric and lung cancers.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a mendelian randomization study design not clinical trialFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Biobank Japan obtained informed consent from the study participants and approval from its institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics supporting the findings of this study are available at Biobank Japan https://humandbs.biosciencedbc.jp/en/hum0014-v19#41diseases